Osteoporosis Management in Women Who Had a Fracture (OMW)
HEDIS Measure
Osteoporosis Management in Women Who Had a Fracture (OMW)
Line of business: Medicare
Data Collection Method: Administrative
Measure Description
The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.
Numerator Compliance
Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:
- A BMD test in any setting, on the IESD or in the 180-day (6-month) period after the IESD.
- If the IESD was an inpatient stay, a BMD test during the inpatient stay.
- Osteoporosis therapy on the IESD or in the 180-day (6- month) period after the IESD.
- If the IESD was an inpatient stay, long-acting osteoporosis therapy during the inpatient stay.
- A dispensed prescription to treat osteoporosis on the IESD or in the 180-day (6-month) period after the IESD.
IESD - Index Episode Start Date. The earliest episode date during the intake period that meets all eligible population criteria.
Best Practices
- Reference The American College of Obstetricians and Gynecologists' Osteoporosis FAQ: www.acog.org/en/Patient%20Resources/FAQs Women's Health/Osteoporosis
- Reference Healthy People gov's Osteoporosis to Prevent Fracture: Screening https://www.healthypeople.gov/2020/tools- resources/evidence-basedresource/osteoporosis-to-prevent- fractures-screening
OSTEOPOROSIS MEDICATIONS
Description | Prescriptions |
---|---|
Bisphosphonates | Alendronate, Alendronate-cholecalciferol, Ibandronate, Risedronate, Zoledronic acid |
Other agents | Abaloparatide, Denosumab, Raloxifene, Romosozumab, Teriparatide |